Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine.

M Strupp, R Kalla, M Dichgans, T Freilinger, S Glasauer, T Brandt

Journal: Neurology 2004;62(9):1623-5

PMID: 15136697

Abstract

Patients with episodic ataxia type 2 (EA2) can often be successfully treated with acetazolamide. The authors report three patients with EA2 (two with proven mutations in the CACNA1A gene) whose attacks were prevented with the potassium channel blocker 4-aminopyridine (4-AP; 5 mg tid). Attacks recurred after treatment was stopped; subsequent treatment alleviated the symptoms (mean follow-up time 6 months). These effects might be due to an improvement of the impaired functioning of Purkinje cells.

Address: Department of Neurology, University of Munich, Germany. [email protected]

DOI: 10.1212/01.wnl.0000125691.74109.53

Link outs

Free resources

Medical:

https://clinicaltrials.gov/search?term=AREA%5BRefe...

Other Literature Sources:

https://www.lens.org/lens/search/patent/list?q=ref...

Molecular Biology Databases:

Subscription / membership required

Full Text Sources:

MeSH Terms: 4-Aminopyridine, Acetazolamide, Adolescent, Adult, Ataxia, Calcium Channels, Humans, Male, Middle Aged, Mutation, Nystagmus, Pathologic, Potassium Channel Blockers, Purkinje Cells, Treatment Outcome